MarketBeat
24 Sept 2026, 06:02 UTC · 2h ago
Verdict
Headline leans bullish. We score DFTX +0.80 across five claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
5 claims · scored −1 bearish … +1 bullish · 2 new · 3 priced in
DT120 achieved statistically significant placebo-adjusted improvements in Phase III trials: 5.4 points (VOYAGE) and 5.1 points (PANORAMA) for GAD, and 8.1 points (EMERGE) for MDD.
Priced indiscussion at a summit regarding 'recent' results
So whatThe p-values below 0.0001 across three trials strongly support a successful NDA filing, which typically triggers a re-rating of the company's valuation multiple.
More positive than 99% of claims this week
Continue reading
5 related stories
More positive than 86% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Definium intends to hold a pre-NDA meeting with the FDA to align on the submission process for GAD and MDD, potentially via sequential or joint filings.
Newstated as current intention by CMO
So whatThis meeting is the final regulatory hurdle before a formal application, placing a potential FDA approval decision within the 2027 horizon.
More positive than 86% of claims this week
Early Part B open-label data shows 60% to 70% of treated patients achieved mild-or-remission outcomes through week six.
Newdata released through week six of Part B
So whatThe convergence of outcomes suggests that repeated dosing (up to 5 per year) can salvage non-responders from the primary 12-week period.
More positive than 77% of claims this week
Phase III remission rates for GAD were 14% in VOYAGE and 15% in PANORAMA, significantly lower than the nearly 50% reported in Phase II.
Priced indiscussion of recent Phase III results
So whatThe ~35% drop in remission rates from Phase II to Phase III may lead analysts to lower peak sales estimates for the drug.
More negative than 79% of claims this week
The post-treatment clearance time for GAD studies was approximately six hours on average, with 97% of patients cleared by eight hours.
Priced indiscussion of recent Phase III results
So whatAn 8-hour window for 97% of patients allows for a single-day clinic workflow, reducing the overhead costs for the anticipated white-bagging distribution model.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
The company reported statistically significant improvements in Phase III trials for its lead product candidate DT120 in treating GAD and MDD.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
11m ago
—
DFTX hasn't traded since this ran. Last close $37.65 (Sep 23); the reaction starts at the next open.
DFTX chart →
